Sep 2026· International Journal of Innovative Technologies in Social Science· 0 citations· 34 references
TL;DR
A thorough analysis of ADC possibilities in oncology focusing on treatment options, side effects of therapies for breast, bladder and lung cancers reveals ADC to be a promising treatment option as a innovative, more precise form of therapy.
Abstract
Background: Antibody-drug conjugates (ADC) are a promising novel therapy for oncology patients as it combines tumor- targeted antibodies with cytotoxic molecules resulting in improved therapeutic outcomes.
Aim: The aim of this article is a thorough analysis of ADC possibilities in oncology focusing on treatment options, side effects of therapies for breast, bladder and lung cancers.
Material and methods: A search of relevant research databases was conducted to identify eligible papers.
Results: Findings reveal ADC to be a promising treatment option as a innovative, more precise form of therapy.
This review systematically summarizes the major mechanisms underlying ADC resistance in BC and outlines potential strategies to overcome it, including the development of next-generation ADCs, combination therapies, and predictive biomarkers.
Kai Liu, Feixiang Xu, Chen-Yang Wu et al.· Frontiers in Pharmacology· 0 citations
The rationale for targeting established and emerging antigens in non-small cell and small cell lung cancer, including HER2, TROP2, c-MET, HER3, CEACAM5, DLL3, and other promising targets currently under clinical investigation are discussed.
P. Paliogiannis, G. Fara, A. Zinellu et al.· Current Issues in Molecular...· 0 citations
Prostate-specific membrane antigen is a transmembrane glycoprotein that is highly specific and overexpressed in prostate cancer cells, making it an effective target for theranostics. Despite significant progress in recent years with prostate-specific membrane antigen-targeting radiopharmaceutical therapies that show pr...
Yang Wang, Jane McKenzie, S. Sandhu· Journal of Nuclear Medicine· 1 citation
In this issue of Cancer Cell, Li et al. report a first-in-human phase 1 study of SYS6010, an epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate, in advanced solid tumors. The study highlights how EGFR-directed therapy moves beyond kinase inhibition toward antigen-guided cytotoxic delivery in non-...
Li-Hui Liu, Kai-Lun Fei, Jie Wang· Cancer Cell· 0 citations
Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer and redefined the conceptual distinction between targeted therapy and conventional chemotherapy. Originally conceived as “magic bullets” that selectively deliver cytotoxic warheads to antigen-expressing tumor cells, clinical and m...
Chen-Xu Guo, L. Ellisen· Journal of Clinical Investig...· 0 citations
Current active clinical trials evaluate new immune checkpoints, including lymphocyte activation gene 3, T cell immunoreceptor with Ig and ITIM domains, and killer Ig-like receptor 2DL1/2L3.
S. Schokrpur, M. G. White, C. Roland et al.· Hematology/Oncology Clinics...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
